Irsogladine
Based on 3 publication(s) in Google Scholar
Irsogladine (Dicloguamine) is an orally active gastric mucosal protective agent. Irsogladine inhibits breast cancer recurrence and lung metastasis in nude mice. Irsogladine inhibits the transcriptional activities of NF-κB and AP-1, suppresses the activities of PDE and PDE4 to elevate intracellular cAMP levels, and activates TRPV1 and KATP channels. Irsogladine enhances iNOS expression, NO production, and the activation of cAMP-responsive elements. Irsogladine inhibits the development and progression of intestinal polyps in Apc-mutant mice. Irsogladine alleviates oxidative stress, increases gastric mucosal blood flow, and stimulates the production of endogenous prostaglandins. Irsogladine promotes insulin secretion in MIN6 cells. Irsogladine inhibits tumor angiogenesis, cancer cell proliferation, and the production of proinflammatory cytokines. Irsogladine exerts protective effects on astrocytes in ethanol/hydrochloric acid-induced gastric ulcers in mice. Irsogladine prevents colitis in IL-10 gene-deficient mice by reducing the production of IL-12 and IL-23. Irsogladine upregulates gap junction intercellular communication in pancreatic cancer cells via the PKA pathway. Irsogladine is applicable to research related to breast cancer, intestinal polyposis, gastric ulcer, spontaneous colitis, glioma, liver cancer, and pancreatic cancer[5][6].
For research use only. We do not sell to patients.
- Purity : 99.88%
- CAS No.: 57381-26-7
- Formula: C9H7Cl2N5
- Molecular Weight:256.09
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
Publications Citing Use of MedChemExpress (MCE) Irsogladine
MoreAll AP-1 Isoforms
More
Biological Activity
Description
IC50 & Target
|
PDE4 |
In Vitro
Irsogladine (1-100 μM; 48 h) inhibits the proliferation of HUVEC and MDA-MB-435 cells by 15% at the concentration of 100 μM[1].
Irsogladine maleate (100-200 μM; 24-48 h) inhibits the transcriptional activity of AP-1 and NF-κB in Caco-2 cells[2].
Irsogladine maleate (100-200 μM; 24 h) inhibits the basal transcriptional activity of NF-κB in HCT-15 cells[2].
Irsogladine (1-10 μM; 24 h) significantly enhances the antiproliferative effects of NO donors SNAP and NONOate on glomerular mesangial cells[4].
Irsogladine (10 μM; 24 h) slightly upregulates the expression of connexin 43 in rat glomerular mesangial cells, and significantly enhances the SNAP (HY-121526)-induced increase in connexin 43 expression in these cells[4].
Irsogladine (10 μM; 1 h) causes a small but significant increase in intracellular cAMP levels in rat glomerular mesangial cells, and exerts a synergistic effect on elevating cAMP levels when used in combination with SNAP in these cells[4].
Irsogladine (10 μM; 1 h) weakly activates PKA in rat glomerular mesangial cells and potently enhances SNAP-induced PKA activation in these cells[4].
Irsogladine (0.1-100 μM; 24 h) synergistically activates CRE[4] in rat glomerular mesangial cells when used in combination with NO donors (SNAP, SNP (HY-B0564), NONOate) or cytokine-induced endogenous NO.
Combination treatment with irsogladine (10 μM; 24 h) and either the sGC activator Bay 41-2272 (HY-12376) or the PDE3-interacting cGMP analog 8-bromo-cGMP (HY-101379A) synergistically activates CRE and PKA in rat glomerular mesangial cells[4].
Irsogladine (10 μM; 24 h) significantly enhances cytokine (TNF-α + IL-1β)-induced iNOS expression and NO production in rat glomerular mesangial cells[4].
Irsogladine (1.0×10-8-1.0×10-5 M; 30 min pre-incubation, 60 min co-incubation with glucose) increases insulin secretion by 1.7-fold at a concentration of 1.0×10-5 M, and this effect depends on functional gap junctions and the cAMP-PKA pathway[5].
Irsogladine (1.0×10-5 M; 30 min) increases the levels of plasma membrane-associated Cx36 protein and cAMP in MIN6 cells[5].
Irsogladine (10-7-10-4 M; 24 h) dose-dependently inhibits the gene expression and protein secretion of IL-12p40 and IL-23p19, suppresses IL-23 secretion, and reduces TNF-α mRNA expression in J774A.1 mouse monocyte/macrophage cells[6].
Irsogladine (10-6-10-4 M; 5 days) specifically inhibits the proliferation of human microvascular endothelial cells and human umbilical vein endothelial cells[7].
Irsogladine (10-6-10-4 M; 3 days) inhibits U251-induced tube formation in human microvascular endothelial cells[7].
Irsogladine malate (10-6 M; administered for 3-5 days until 90-95% confluence) significantly upregulates GJIC between human pancreatic cancer cells PANC-1[8].
Irsogladine malate (10-8-10-6 M; treated for 3-5 days until 90-95% confluence) dose-dependently increases the levels of phosphorylated Cx43 (P1, P2) in the membrane fraction of human pancreatic cancer cell line PANC-1[8].
Irsogladine malate (10-6 M; treated for 3-5 days until 90-95% confluence) induces the relocalization of Cx43 protein from the cytoplasm to the intercellular borders in human pancreatic cancer cells PANC-1[8].
Irsogladine malate (10-6 M; treated for 3-5 days until 90-95% confluence) significantly increases intracellular cAMP levels in PANC-1 human pancreatic cancer cells[8].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:HUVEC cells, MDA-MB-435 cells
-
Concentration:1 μM; 10 μM; 100 μM
-
Incubation Time:48 h
-
Result:Inhibited the proliferation of HUVEC and MDA-MB-435 cells by 15% at 100 μM.
Had no effect on proliferation of either cell line at 1 μM and 10 μM.
-
Cell Line:rat glomerular mesangial cells (SM43 line)
-
Concentration:1 μM, 10 μM
-
Incubation Time:24 h
-
Result:Did not affect PDGF-induced mesangial cell proliferation at 10 μM.
Significantly potentiated the anti-proliferative effect of the NO donor SNAP at 1 μM.
Potentiated the anti-proliferative effect of the NO donor NONOate at 1 μM.
Showed no cytotoxic effects at 1, 10 μM when evaluated by LDH release.
-
Cell Line:rat glomerular mesangial cells
-
Concentration:10 μM
-
Incubation Time:24 h
-
Result:Modestly elevated Cx43 expression in mesangial cells when used alone.
Greatly potentiated the concentration-dependent SNAP-induced elevation of Cx43 levels when combined with SNAP (1, 10, 100 μM).
-
Cell Line:rat glomerular mesangial cells
-
Concentration:10 μM
-
Incubation Time:1 h
-
Result:Induced a slight increase in VASP serine 157 phosphorylation when used alone.
Potently induced VASP serine 157 phosphorylation, reflecting strong PKA activation, when combined with 100 μM SNAP.
-
Cell Line:mouse insulin-secreting MIN6 cells
-
Concentration:1.0×10-8 M, 1.0×10-7 M, 1.0×10-6 M, 1.0×10-5 M
-
Incubation Time:30 min (pre-incubation); 60 min (co-incubation with glucose)
-
Result:Had no effect on insulin secretion under 5.6 mM glucose conditions.
Induced a 1.7 fold increase in insulin secretion compared to control under 16.8 mM glucose conditions.
Showed this insulin secretion-inducing effect was inhibited by co-treatment with a gap junction inhibitor, pre-treatment with Rp-cAMP, or co-treatment with H89.
-
Cell Line:human microvascular endothelial cells, human umbilical endothelial cells, human glioma U251 cells, human epidermoid cancer KB cells
-
Concentration:10-6 M, 10-5 M, 10-4 M
-
Incubation Time:5 days
-
Result:Inhibited the proliferation of human microvascular endothelial cells and human umbilical endothelial cells by >30% of control levels.
Did not affect the proliferation of human glioma U251 cells or human epidermoid cancer KB cells.
-
Cell Line:PANC-1 human pancreatic cancer cells
-
Concentration:10-6 M
-
Incubation Time:3-5 days (until 90-95% confluence)
-
Result:Induced Cx43 immunofluorescence to appear as large spots or short lines at the boundaries between adjacent cells, indicating relocalization from the cytoplasm (particularly perinuclear regions in untreated cells) to cell-cell junctions.
Had this relocalization inhibited by co-treatment with H-89 or SQ22536.
-
Cell Line:PANC-1 human pancreatic cancer cells
-
Concentration:10-6 M
-
Incubation Time:3-5 days (until 90-95% confluence)
-
Result:Increased intracellular cAMP levels by approximately fivefold relative to untreated controls.
Showed a significant increase.
In Vivo
Irsogladine maleate (5-50 ppm; administered via diet; ad libitum access; 8 weeks) inhibits intestinal polyp formation in male Min mice (reducing the total number of polyps to 69.3% and 66.1% of that in the control group, respectively), and its mechanism of action involves, in part, inhibition of the NF-κB signaling pathway and reduction of reactive carbonyl species associated with oxidative stress[2].
Irsogladine maleate (ad libitum access for 25 consecutive weeks) inhibits the development of gastrointestinal tumors in male Wistar rats with gastric carcinogenesis initiated by N-methyl-N'-nitro-N-nitrosoguanidine and promoted by glyoxal[2].
Irsogladine maleate (125 ppm; administered via diet; ad libitum access; 35 weeks) completely inhibits liver tumorigenesis (0% incidence) in male F344 rats initiated with diethylnitrosamine and promoted with phenobarbital[2].
Irsogladine (1-10 mg/kg; p.o.; single administration; 1 h prior to ulcer induction) exerts a dose-dependent gastroprotective effect against ethanol/hydrochloric acid-induced gastric ulcers in male ICR mice, with an 84.2% injury inhibition rate at the dose of 10 mg/kg. Its action is partially mediated by elevated cAMP levels, enhanced prostaglandin activity, opening of KATP channels, and antioxidant properties[3].
Irsogladine (100 ppm; p.o.; daily; for 10 consecutive weeks) prevents spontaneous colitis in IL-10−/− mice by reducing the colonic histological score to 1.6 and inhibiting cytokine expression in the Th1/Th17 pathway via suppression of IL-12 and IL-23 production[6].
Irsogladine (30-120 mg/kg; p.o.; daily; for 4 consecutive weeks) dose-dependently inhibits glioma tumor growth and reduces tumor microvessel density in BALB/c nu/nu mice. Specifically, the dose of 60 mg/kg/day reduces tumor volume by approximately 50%, while the dose of 120 mg/kg/day decreases microvessel count to approximately 30% of the control level[7].
Irsogladine (30-60 mg/kg; p.o.; daily; for 7 consecutive days) inhibits liver cancer-induced tumor neovascularization in the dorsal air sac of mice. Specifically, the dose of 60 mg/kg/day completely blocks the formation of tumor-specific neovasculature without affecting pre-existing blood vessels[7].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c nude (female, 6-8 weeks old, human MDA-MB-435 breast cancer cell mammary fat pad injection model)[1]
-
Dosage:120 mg/kg
-
Administration:p.o.; daily; 5 weeks
-
Result:Inhibited primary tumor regrowth by 39.6%.
Reduced pulmonary metastasis incidence, with 31% of treated mice free of pulmonary metastases.
Inhibited mean volume of pulmonary metastases by 48.4%.
Did not affect mouse body weight.
-
Animal Model:C57BL/6-ApcMin/+ (male, 5 weeks of age)[2]
-
Dosage:5 ppm; 50 ppm
-
Administration:dietary; ad libitum; 8 weeks
-
Result:Reduced total intestinal polyp number to 69.3% of control, proximal small intestine polyps to 61.5% of control, distal small intestine polyps to 21.9% of control, polyps <0.5 mm and 1.5-2.0 mm in diameter, serum triglyceride levels to 42.1% of control, and suppressed IL-1β mRNA levels in polyps to 85% of control, IL-6 mRNA levels in polyps to 51% of control, and reduced levels of 194 hepatic reactive carbonyl species peaks, and significantly reduced levels of specific reactive carbonyl species including acetaldehyde, acrolein, pentanal, hexanal, 2,4-NDE, 2-nonenal, HNE, decanal, undecanal, dodecanal, tridecanal, tetradecanal, hexadecanal, 8-HpDE, and heptadecanal at 5 ppm.
Reduced total intestinal polyp number to 66.1% of control, proximal small intestine polyps to 53.8% of control, middle small intestine polyps to 39.7% of control, polyps <0.5 mm and 0.5-1.0 mm in diameter, serum triglyceride levels to 73.4% of control, and reduced levels of 163 hepatic reactive carbonyl species peaks, and significantly reduced levels of specific reactive carbonyl species including acrolein, pentanal, 2-hexenal, hexanal, 2,4-NDE, 2-nonenal, HNE, tetradecanal, hexadecanal, and heptadecanal at 50 ppm.
Did not affect body weight, food intake, clinical signs, organ weights, gastric histopathology, serum free fatty acid or total cholesterol levels, and only slightly reduced PCNA-positive cell percentage in polyps (not statistically significant) at both doses.
-
Animal Model:F344 (male)[2]
-
Dosage:125 ppm
-
Administration:dietary; ad libitum; 35 weeks
-
Result:Prevented the development of liver neoplasms, with an incidence of 0/14 rats.
-
Animal Model:ICR (male, 25-30 g)[3]
-
Dosage:1 mg/kg; 10 mg/kg
-
Administration:p.o.; single dose; 1 hour before ulcer induction
-
Result:Reduced gastric mucosal injury area to 7.86 mm2, achieving 15.0% inhibition of ethanol/HCl-induced lesions compared to vehicle.
Showed slight reduction of gastric mucosal damage via histological analysis.
Reduced gastric mucosal injury area to 1.42 mm2, achieving 84.2% inhibition of ethanol/HCl-induced lesions compared to vehicle.
Showed near-restoration of normal gastric mucosa via histological analysis.
Increased gastric mucosal cAMP levels to 5.8 pmol/mg protein (165% of vehicle levels); when combined with S-nitroso acetyl penicillamine, cAMP levels synergistically increased to 8.3 pmol/mg protein (243% of vehicle levels).
Reduced ethanol/HCl-induced mucosal lesions to 8.4% of total gastric size; this effect was slightly reversed by the K_ATP channel blocker glibenclamide, and slightly reduced by the TRPV1 antagonist capsazepine and cyclooxygenase inhibitor indomethacin.
Reduced thiobarbituric acid reactive substances (TBARS) levels to 40.5 nM/g tissue at 1 mg/kg; reduced TBARS levels to 28.9 nM/g tissue at 10 mg/kg, indicating inhibition of lipid peroxidation.
-
Animal Model:IL-10−/− (5 weeks old, gender ratio balanced)[6]
-
Dosage:100 ppm
-
Administration:oral; daily; 10 consecutive weeks
-
Result:Increased mean colon length significantly.
Reduced mean colon weight significantly.
Reduced mean histological colitis score from 3.8 to 1.6.
Suppressed colonic tissue mRNA expression of proinflammatory cytokines: TNF-α (-2.5-fold), IL-1β (-5.4-fold), IFN-γ (-4.5-fold), IL-17 (-113.0-fold), IL-12p35 (-21.0-fold), IL-12p40 (-3.4-fold), and IL-23p19 (-4.2-fold) relative to controls.
Showed no significant difference in body weight gain compared to controls over the 10-week period.
Reduced colonic wall thickening and redness compared to controls.
-
Animal Model:BALB/c nu/nu (male, 5 weeks old, ~20 g, subcutaneous implantation of human glioma U251 cells)[7]
-
Dosage:30 mg/kg; 60 mg/kg; 120 mg/kg
-
Administration:p.o.; daily; 4 weeks
-
Result:Reduced average tumor volume to ~50% of control at 60 mg/kg/day, with greater reduction at 120 mg/kg/day.
Reduced factor VIII-positive microvessels per ×100 field to ~95 at 30 mg/kg/day, ~60 at 60 mg/kg/day, and ~35 at 120 mg/kg/day (control ~115).
Did not affect mouse body weight at any dose.
-
Animal Model:(implantation of diffusion chambers with human hepatic cancer HepG2 cells into dorsal air sacs)[7]
-
Dosage:30 mg/kg; 60 mg/kg
-
Administration:p.o.; daily; 7 days
-
Result:Reduced the development of HepG2-induced tumor neovasculatures, with only short neovasculatures observed at 30 mg/kg/day.
Almost completely eliminated the appearance of HepG2-induced tumor neovasculatures at 60 mg/kg/day.
Did not affect preexisting blood vessels at 60 mg/kg/day.
Chemical Information
-
CAS No. 57381-26-7
-
Appearance Solid
-
Molecular Weight 256.09
-
Formula C9H7Cl2N5
-
Color White to off-white
-
SMILES
NC1=NC(N)=NC(C2=CC(Cl)=CC=C2Cl)=N1
-
Synonyms
Dicloguamine
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (3)
-
Journal Impact Factor
-
Most Recent
-
Anal Chem
Exposome-Scale Investigation of Cl-/Br-Containing Chemicals Using High-Resolution Mass Spectrometry, Multistage Machine Learning, and Cloud Computing. [Abstract]2025 Jun 3;97(21):11099-11109. PMID: 40401576 -
Cell Rep Methods
RECOVER identifies synergistic drug combinations in vitro through sequential model optimization. [Abstract]2023 Oct 23;3(10):100599. PMID: 37797618 -
Solvent & Solubility
In Vitro:
DMSO : 120 mg/mL (468.59 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : < 0.1 mg/mL (insoluble)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: 3 mg/mL (11.71 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 3 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (30.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocols
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
Human pluripotent stem cell endothelial-cell differentiation
Human pluripotent stem cell endothelial differentiation is based on stepwise developmental patterning: early activation of WNT/GSK3β inhibition promotes mesodermal or vascular progenitor entry, followed by endothelial specification using VEGF-related signaling, BMP4, FGF2, Notch modulation, or cAMP depending on the published protocol. Endothelial differentiation is read out by acquisition of CD31, CD34, VE-cadherin/CD144, KDR/VEGFR2, vWF, Tie2, NOS3, acetylated LDL uptake, tube/network formation, barrier function, and in vivo vessel-forming capacity where tested.
-
Somatic Cell Culture
A method of simulating the in vivo environment in vitro to maintain the cell growth, differentation and main functions.
-
Human Islet Cell Culture
The method of preserving islets in vitro, with purified reduced immunogenicity. The steps are islet isolation, islet cell purification, in vitro determination of islet function and islet cell culture.
-
Liver Cancer Modeling
Liver cancer can be classified into primary liver cancer and secondary liver cancer. Secondary liver cancer is the metastatic liver cancer. Primary liver cancer includes hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (ICC) and fibrolamellar HCC, of which HCC is the most common form, accounting for approximately 90% of primary liver cancers[1]. HCC mouse models include chemical agent-induced models, transplanted tumor models, and genetic engineered models.
-
Breast Cancer Modeling
Breast cancer is a heterogeneous cancer, and it has been distinguished into four subtypes: luminal A, luminal B, HER2-positive and basal-like. Molecular mutations, epigenetic alterations, hormone exposure and immune microenvironment are related to the progression of breast cancer.
-
Research Protocol for Endocrine Diseases
Endocrine diseases often arise from disrupted hormone production, hormone signaling, or target-tissue responsiveness; for diabetes-focused endocrine disease models, insulin signaling regulates glucose uptake, hepatic glucose output, lipid metabolism, and β-cell compensation. Type 2 diabetes develops through interacting defects in insulin resistance, β-cell dysfunction, adipose inflammation, hepatic glucose overproduction, altered incretin signaling, and ectopic lipid metabolism. A major unresolved question is whether endocrine dysfunction is driven primarily by target-tissue insulin resistance, intrinsic β-cell failure, immune/inflammatory stress, or combined multi-organ failure that differs by disease stage.
-
Endothelial Tube Formation Assay
Endothelial tube formation assay evaluates the ability of endothelial cells to attach, migrate, align, and organize into capillary-like networks when cultured on gelled basement membrane extract or Matrigel; the readout is the morphology and quantity of tube-like networks, which reflects an in vitro endothelial morphogenesis step related to angiogenesis. Basement membrane extract/Matrigel provides laminin-rich extracellular matrix cues that support endothelial differentiation into capillary-like structures, but it can contain biologically active growth factors, so growth-factor-reduced matrix is preferred when testing defined angiogenic stimulators or inhibitors.
-
MTT Cell Proliferation Assay
The MTT assay is a colorimetric endpoint assay for estimating viable cell number, cell growth, cytotoxicity, or cell activation in cultured mammalian cells. Living cells reduce the yellow tetrazolium salt MTT into purple/blue formazan, while dead cells do not generate the same signal; the resulting color can be quantified with a multiwell spectrophotometer. MTT reduction is commonly interpreted as a readout of metabolic activity that often correlates with viable cell number, but it should not be treated as a direct cell-counting method unless the assay is optimized for the cell type and experimental condition. Studies show that MTT reduction can involve mitochondrial and non-mitochondrial reducing systems, and formazan may accumulate in intracellular lipid droplets rather than simply marking mitochondria.
-
Endothelial Cell Migration/Angiogenic Sprouting Assay
Endothelial cell migration and angiogenic sprouting assays are in vitro (and partially ex vivo-adapted) functional models that quantify the ability of endothelial cells to undergo coordinated migration, extracellular matrix invasion, and multicellular organization into capillary-like sprouts in response to pro-angiogenic stimuli such as VEGF, bFGF, or conditioned microenvironments. These assays are used to model early angiogenic events including tip-cell formation, directional migration, and lumen-like sprout extension, which collectively reflect angiogenic activation and vascular morphogenesis processes observed in vivo.
-
Vascular/Branching Fractal Analysis
Vascular/branching fractal analysis quantifies the geometric complexity of vessel trees or vascular networks from segmented 2D images, commonly by converting vessels into binary and/or skeletonized maps and estimating fractal dimension using box-counting or related approaches. Fractal dimension is interpreted as an image-derived readout of vascular branching complexity, space filling, or density, and has been applied to retinal photographs, fluorescein angiography, OCT angiography, capillary perfusion maps, and in vitro Matrigel angiogenesis networks. The assay readout is generated from vessel-positive pixels after image preprocessing, vessel segmentation, binarization, and optional skeletonization; reported outputs include fractal dimension, vessel density, branchpoint density, endpoint density, vessel length density, tortuosity, and generation-based branching metrics when VESGEN-style analysis is used. The biological interpretation is limited to quantitative vascular patterning and s
-
ROS/oxidative-stress fluorescent staining
ROS/oxidative-stress fluorescent staining uses cell-permeant fluorogenic probes that become fluorescent after oxidation inside cells or tissues; commonly used examples include DCFH-DA/DCFDA for broad cellular oxidant detection, DHE for superoxide-related signal detection, MitoSOX for mitochondrial superoxide-related signal detection, and CellROX probes for oxidative-stress-associated fluorescence readouts. The assay detects probe oxidation rather than a single ROS species unless the probe and analysis method have been chemically validated for that species. DCFH-DA enters cells, is deacetylated by intracellular esterases to DCFH, and produces fluorescent DCF after oxidation, so the readout is used as an operational measure of total cellular oxidative stress rather than a species-specific ROS measurement. DHE and MitoSOX can report superoxide-related oxidation, but red fluorescence alone can include non-specific ethidium-like oxidation products; HPLC or optimized spectral approaches are
-
BrdU Incorporation Assay
Bromodeoxyuridine (BrdU) incorporation assay is based on the principle that BrdU, a thymidine analog, is incorporated into newly synthesized DNA during the S phase of the cell cycle, thereby serving as a marker of DNA replication and cellular proliferation. Incorporated BrdU can be detected using anti-BrdU antibodies following DNA denaturation, enabling visualization or quantification of proliferating cells through immunochemical detection methods such as immunofluorescence or immunohistochemistry.
-
CFSE Dye Dilution Proliferation Assay
The CFSE (carboxyfluorescein diacetate succinimidyl ester) dye dilution proliferation assay is based on the covalent labeling of intracellular proteins by a cell-permeant fluorescent dye that becomes fluorescent upon intracellular ester cleavage and then is stably retained within cells. As labeled cells divide, the dye is partitioned equally between daughter cells, resulting in a stepwise halving of fluorescence intensity that can be quantified by flow cytometry to determine the number of cell divisions undergone by each cell population. This fluorescence dilution approach enables quantitative tracking of lymphocyte proliferation at the single-cell level over multiple rounds of division. CFSE-based proliferation analysis has been widely applied to measure antigen-driven lymphocyte expansion in vitro, where discrete fluorescence peaks correspond to successive cell divisions and allow reconstruction of proliferative history within heterogeneous populations.
-
Dye-dilution cell tracking and proliferation staining
Dye-dilution cell tracking assays quantify cell proliferation by covalently labeling intracellular proteins with a stable fluorescent dye that is equally partitioned between daughter cells during mitosis, resulting in stepwise halving of fluorescence intensity with each cell division as measured by flow cytometry histograms. Carboxyfluorescein diacetate succinimidyl ester (CFSE) is a prototypical dye that diffuses into cells, is enzymatically converted into a fluorescent compound, and then covalently binds intracellular amine groups, producing long-lived fluorescence suitable for tracking multiple rounds of division in vitro and in vivo. Successive generations of dividing cells form discrete peaks of decreasing fluorescence intensity, enabling estimation of proliferation history, precursor frequency, and division index within heterogeneous populations. Alternative dyes such as CellTrace Violet (CTV) and far-red membrane dyes (e. g. , PKH26) follow the same dilution principle but differ
-
CCK-8/WST-8 Cell Proliferation Assay
The CCK-8/WST-8 assay is based on the reduction of the water-soluble tetrazolium salt WST-8 to a water-soluble formazan product by cellular dehydrogenases in metabolically active cells, where the generated formazan amount is proportional to the number of living cells and is quantified by measuring absorbance in the visible range, providing a colorimetric readout for cell viability and proliferation assessment. This class of tetrazolium-based assays improves upon earlier MTT-based systems by producing a water-soluble formazan, eliminating the need for organic solubilization steps and enabling direct spectrophotometric measurement in culture medium.
-
Protocol for Cell Cycle
Cell-cycle analysis by flow cytometry measures DNA content in single cells to estimate the fraction of cells in G0/G1, S, and G2/M phases. Propidium iodide intercalates into DNA, and after RNA removal with RNase, fluorescence intensity reflects cellular DNA content: 2N cells are assigned to G0/G1, cells between 2N and 4N to S phase, and 4N cells to G2/M. DNA-content analysis alone cannot reliably separate G0 from G1 or G2 from M. Ki-67 can distinguish quiescent G0 cells from cycling cells, EdU or BrdU incorporation marks active DNA synthesis in S phase, and phospho-histone H3 staining identifies mitotic cells within the 4N population.
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
-
Cell Counting-Based Growth Curve Assay
Cell counting-based growth curve assays quantify cell proliferation by directly measuring changes in viable cell number over time using manual or automated counting methods such as hemocytometer-based counting or instrument-assisted cell enumeration, enabling construction of growth curves that reflect population expansion dynamics in response to culture conditions. A widely used approach is trypan blue exclusion with hemocytometer counting, where membrane-compromised (non-viable) cells take up the dye, allowing discrimination between viable and non-viable cells while simultaneously enabling total cell number quantification. Repeated sampling across time points allows estimation of proliferation rate, growth phases, and comparative growth kinetics between experimental conditions.
-
Colony Formation (Clonogenic) Assay
The clonogenic (colony formation) assay measures the ability of a single cell to retain reproductive viability and form a macroscopic colony, typically defined as a cluster derived from one progenitor cell after a defined growth period. This assay is widely used to evaluate cell survival after exposure to ionizing radiation or cytotoxic treatments and is considered a standard method in radiation biology for generating dose-response relationships of reproductive cell death. Colony formation reflects long-term proliferative capacity rather than short-term metabolic activity, and survival is quantified by comparing treated versus untreated conditions based on colony number and derived survival fractions.
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
-
EdU Incorporation Assay (Click Chemistry-Based DNA Synthesis Measurement)
The EdU incorporation assay measures DNA synthesis by adding the thymidine analog 5-ethynyl-2′-deoxyuridine to cells or tissues, where it is incorporated into newly synthesized DNA during S phase. Incorporated EdU is detected by copper-catalyzed azide-alkyne cycloaddition, in which a fluorescent azide covalently reacts with the ethynyl group on EdU, allowing S-phase cells to be detected by fluorescence microscopy, flow cytometry, or high-content imaging. EdU detection does not require DNA denaturation or anti-BrdU antibody access, which preserves sample structure and improves compatibility with immunostaining and multiparameter cytometry compared with BrdU-based detection. EdU can be cytotoxic in a cell-type- and exposure-dependent manner, so pulse duration, concentration, and continuous-labeling designs should be validated for each cell type.
-
Ki-67 Immunostaining Proliferation Assay
Ki-67 immunostaining measures the growth fraction of a cell population by detecting Ki-67, a nuclear antigen present in proliferating cells and absent in quiescent G0 cells. The readout is the percentage of Ki-67-positive nuclei among total counted cells, commonly called the Ki-67 labeling index or proliferation index.
-
PCNA Immunodetection Proliferation Assay
PCNA immunodetection measures proliferative activity by detecting proliferating cell nuclear antigen, a nuclear protein associated with DNA polymerase δ function and DNA replication. The assay readout is the proportion of PCNA-positive nuclei among total counted cells, but PCNA labeling is not identical to BrdU labeling because PCNA can mark late G1/early S-associated replication competence and may persist beyond active DNA synthesis depending on fixation and extraction conditions.
-
Protocol for Cell Counting and Cell Density Analysis
Cell counting and cell-density analysis estimate the number of cells in a known volume or field area. Manual hemocytometer counting uses a chamber of defined geometry to convert counted cells into cells/mL, while automated counters and image-analysis workflows detect cell objects from optical, brightfield, fluorescence, impedance, or digital-image features. Trypan blue viability counting is based on dye exclusion: viable cells with intact membranes exclude dye, while non-viable cells with compromised membranes stain blue. The readout is total cell density, viable-cell density, dead-cell density, and percent viability. Cell density can also be estimated from microscopy images by counting objects per image area, from flow cytometry using calibrated volume or reference particles, or from in situ microscopy in bioreactors after calibration against reference methods such as hemocytometer or flow cytometry.
-
DSS-Induced Colitis
Dextran sulfate sodium (DSS)-induced colitis is generated by administering DSS in mouse drinking water, producing epithelial injury, barrier disruption, weight loss, diarrhea, fecal blood, colon shortening, histologic mucosal damage, and inflammatory mediator changes; the model is mainly used to study acute or chronic intestinal inflammation resembling selected features of ulcerative colitis. DSS injury is interpreted through clinical and tissue readouts rather than a single molecular endpoint: daily body weight, stool consistency, and bleeding are combined into a disease activity index, while colon length, histology, cytokines, myeloperoxidase activity, intestinal permeability, and tight-junction markers provide complementary measures of inflammation and barrier damage.
-
TNBS-Induced Colitis
TNBS-induced colitis is produced by intrarectal delivery of 2,4,6-trinitrobenzene sulfonic acid in ethanol, where ethanol disrupts the mucosal barrier and TNBS haptenates colonic proteins, generating immune-mediated colonic inflammation with weight loss, diarrhea, ulceration, transmural injury, inflammatory-cell infiltration, and cytokine responses. The model is used as an experimental intestinal inflammation model with Crohn’s disease–like features, especially when Th1-type responses, IL-12–dependent inflammation, chronic relapsing inflammation, or fibrosis-related endpoints are studied.
-
Tail-Vein Experimental Metastasis Xenograft
Tail-vein experimental metastasis xenograft models assess the ability of injected tumor cells to survive circulation, arrest in vascular beds, extravasate, and colonize distant organs, most commonly lung after lateral tail-vein injection; this model bypasses primary-tumor formation, local invasion, and intravasation, so the readout reflects late metastatic colonization rather than the full metastatic cascade. The main readouts are metastatic burden measured by bioluminescence imaging, gross metastatic nodules, histology, organ weight, survival, or ex vivo tumor-cell quantification; luciferase-labeled tumor cells permit longitudinal noninvasive monitoring, while histology confirms organ colonization and tissue localization.
-
Orthotopic Cell-Line Xenograft
Orthotopic cell-line xenograft models involve implantation of human cancer cell lines into the anatomically corresponding organ of immunodeficient mice to reproduce tumor growth within a native microenvironment, enabling more clinically relevant tumor behavior compared with subcutaneous models. These models are widely used because orthotopic placement better recapitulates tumor progression, including invasion and metastatic spread, which are often underrepresented in heterotopic implantation systems. Compared with conventional xenografts, orthotopic implantation is described as more technically complex but provides improved simulation of tumor-microenvironment interactions and metastatic behavior, making it particularly valuable for translational oncology research. Surgical orthotopic implantation approaches have been emphasized as enabling faithful reproduction of clinical cancer features, including metastasis and disease progression patterns that align with the tumor’s organ of origi
Purity & Documentation
-
Data Sheet (303 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Nozaki S, et al. Inhibition of breast cancer regrowth and pulmonary metastasis in nude mice by anti-gastric ulcer agent, irsogladine. Breast Cancer Res Treat. 2004;83(3):195-199. [Content Brief]
[2]. Onuma W, et al. Irsogladine maleate, a gastric mucosal protectant, suppresses intestinal polyp development in Apc-mutant mice. Oncotarget. 2016;7(8):8640-8652. [Content Brief]
[3]. Kwon SC, et al. Gastroprotective effects of irsogladine maleate on ethanol/hydrochloric acid induced gastric ulcers in mice. Korean J Intern Med. 2021;36(1):67-75. [Content Brief]
[4]. Yao J, et al. Irsogladine maleate potentiates the effects of nitric oxide on activation of cAMP signalling pathways and suppression of mesangial cell mitogenesis. Br J Pharmacol. 2007;151(4):457-466. [Content Brief]
[5]. Matsumoto T, et al. The anti-ulcer agent, irsogladine, increases insulin secretion by MIN6 cells. Eur J Pharmacol. 2012;685(1-3):213-217. [Content Brief]
[6]. Nakagawa T, et al. Irsogladine Maleate Prevents Colitis in Interleukin-10 Gene-Deficient Mice by Reducing Interleukin-12 and -23 Production. Biol Pharm Bull. 2015;38(11):1681-1688. [Content Brief]
[7]. Ono M, et al. Inhibition of tumor growth and neovascularization by an anti-gastric ulcer agent, irsogladine. Cancer Res. 1996 Apr 1;56(7):1512-6. [Content Brief]
[8]. Kawasaki Y, et al. Irsogladine malate up-regulates gap junctional intercellular communication between pancreatic cancer cells via PKA pathway. Pancreas. 2002;25(4):373-377. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.9049 mL | 19.5244 mL | 39.0488 mL | 97.6219 mL |
| 5 mM | 0.7810 mL | 3.9049 mL | 7.8098 mL | 19.5244 mL | |
| 10 mM | 0.3905 mL | 1.9524 mL | 3.9049 mL | 9.7622 mL | |
| 15 mM | 0.2603 mL | 1.3016 mL | 2.6033 mL | 6.5081 mL | |
| 20 mM | 0.1952 mL | 0.9762 mL | 1.9524 mL | 4.8811 mL | |
| 25 mM | 0.1562 mL | 0.7810 mL | 1.5620 mL | 3.9049 mL | |
| 30 mM | 0.1302 mL | 0.6508 mL | 1.3016 mL | 3.2541 mL | |
| 40 mM | 0.0976 mL | 0.4881 mL | 0.9762 mL | 2.4405 mL | |
| 50 mM | 0.0781 mL | 0.3905 mL | 0.7810 mL | 1.9524 mL | |
| 60 mM | 0.0651 mL | 0.3254 mL | 0.6508 mL | 1.6270 mL | |
| 80 mM | 0.0488 mL | 0.2441 mL | 0.4881 mL | 1.2203 mL | |
| 100 mM | 0.0390 mL | 0.1952 mL | 0.3905 mL | 0.9762 mL |
Keywords
- Irsogladine
- 57381-26-7
- Dicloguamine
- Phosphodiesterase (PDE)
- NF-κB
- AP-1
- TRP Channel
- Interleukin Related
- gastric mucosal protective agent
- HUVEC
- MDA-MB-435 cells
- Caco-2 cells
- HCT-15 cells
- J774A.1 cells
- PANC-1 cells
- BALB/c nude mice
- C57BL/6-ApcMin/+mice
- F344rat
- ICRmice
- IL-10?/? mice
- breast cancer
- intestinal polyposis
- gastric ulcer
- spontaneous colitis
- glioma
- liver cancer
- pancreatic cancer
- Inhibitor
- inhibitor
- inhibit